SPRY vs STE · rev $89.1M vs P/E 25, rev $5.46B
ARS Pharmaceuticals, Inc (SPRY) versus STERIS plc (STE) — a side-by-side from cached financials, not a winner call.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
STERIS plc (STE) is a medical devices company listed on NYSE.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
Latest reported STE revenue for 2025-03-31 was $5.46B. Net income was $616.1M. Revenue was up 284.6% from 2024-03-31 to 2025-03-31. STE currently screens at market cap $19.43B and trailing P/E 25.1.
SPRY currently screens at market cap $983.1M. STE currently screens at market cap $19.43B and trailing P/E 25.1.
Not investment advice. Open the SPRY and STE stock pages for the full models.
Not investment advice.